Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15335320 | 1.00 | LPL (0.35) | LPLLIPGMAPK1P2RX7JAK2 | |
| SCHEMBL16043929 | 0.90 | LPL (0.35) | LPLLIPGMAPK1P2RX7JAK2 | |
| SCHEMBL2027004 | 0.88 | LPL (0.34) | LPLLIPGMAPK1P2RX7JAK2 | |
| SCHEMBL15056617 | 0.84 | MAPK1 (0.34) | LPLLIPGMAPK1P2RX7 | |
| SCHEMBL10159440 | 0.82 | P2RX7 (0.34) | LPLLIPGMAPK1P2RX7 | |
| SCHEMBL1646761 | 0.81 | LPL (0.44) | LPLLIPGMAPK1P2RX7JAK2 | |
| SCHEMBL30955785 | 0.81 | ALDH1A1 (0.39) | LPLLIPGJAK2BTK | |
| SCHEMBL13035936 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL16042213 | 0.79 | LPL (0.35) | LPLLIPGJAK2BTK | |
| SCHEMBL20408805 | 0.79 | MAPK1 (0.34) | MAPK1P2RX7JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |